Papa will take over the over effective immediately.
Joseph C. Papa is the new CEO of Emergent BioSolutions.
Papa will step into the role as of February 21, 2024, according to a press release from the company.1 He is taking over from interim CEO Haywood Miller.
Emergent Biosolution's lead product is the Narcan Nasal Spray, an over-the-counter opioid overdose treatment.
In a press release, Papa said, “Whether it’s increasing access to Narcan® Nasal Spray, which is helping combat the opioid epidemic, or continuing to deliver important medical countermeasures to customers around the world, Emergent is providing critical products to address global health crises. I am confident that these important products provide for a bright future ahead as Emergent continues to lead in public health preparedness. I look forward to working with the team to accelerate the company’s progress, continue improving its financial position and drive value for shareholders. It is a privilege to join Emergent and chart a new chapter in this vital space.”
According to the press release, Papa will focus on returning the company to growth while also making moves to pay down the company’s debt. Prior to joining Emergent, Papa served as CEO at Bausch and Lomb Corporation, where he led the company’s IPO. At the time, the company was able to raise $630 million under Papa’s leadership.
In the same press release, Emergent’s chairman of the board of directors Zsolt Harsanyi, Ph.D., said, “Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent. He is a recognized industry leader with unparalleled experience in all facets of the pharmaceutical and healthcare industry. Joe has a solid track record of driving growth and successfully navigating companies through periods of transformation. His leadership will be instrumental in strengthening Emergent’s balance sheet and returning to growth, as we continue to deliver on our mission to protect and enhance life. On behalf of the Board, I would also like to thank Haywood Miller for his leadership and contributions during this interim period.”
Haywood Miller, the interim CEO, said that he was encouraged by the company’s ability to strengthen in financial foundation in recent months. ““It has been an honor to lead Emergent during this period of transition, and I am confident the company is well positioned for the future as a leader in global preparedness and public health,” he said.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.